Systemic Candidiasis is an indication for drug development with over 20 pipeline drugs currently active. According to GlobalData, preregistered drugs for Systemic Candidiasis have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Systemic Candidiasis compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Systemic Candidiasis overview
Systemic candidiasis encompasses a range of yeast infections resulting from various species of Candida, presenting a severe threat that can impact diverse areas of the body such as the blood, heart, brain, eyes, bones, and other organs. While there are over 200 Candida species, five specific types contribute to 90% of systemic candidiasis cases. The primary manifestation of this invasive yeast infection occurs when Candida infiltrates the bloodstream, leading to candidemia. Indications of candidemia include persistent fever and chills unresponsive to antibiotics. Symptoms of other forms of Systemic candidiasis vary depending on the affected organ or system. Particularly prevalent among hospitalized individuals in high-income countries, including the US, systemic candidiasis poses diagnostic challenges, especially when Candida is not detected in the bloodstream.
See Also:
For a complete picture of PTSR and LoA scores for drugs in Systemic Candidiasis, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
